POST 14 — Epitalon and DSIP

Epitalon

Longevity and sleep. The longevity research is the ambitious claim, the sleep effect is the real one you’ll notice.

What Epitalon is: A four-amino-acid peptide (Ala-Glu-Asp-Gly), synthesized as a version of epithalamin, a pineal gland extract studied by Vladimir Khavinson in Russia over several decades. The Khavinson group is famous for their study of many peptides, long before the US ever heard of them.

What it does. Epitalon activates telomerase extending the protective caps on your chromosomes that shorten with cell division and is a measurement of actual aging. Khavinson’s group published long-term human data reporting reduced mortality in elderly subjects, and animal work showing extended lifespan.

Also studied for melatonin regulation and sleep. Recommended 7-4 by the FDA panel in July 2026 for insomnia.

The lifespan and telomerase side is less studies. Khavinson’s group has decades of work behind it, including long-term human follow-up reporting reduced mortality in elderly subjects, and that’s more than most longevity compounds can point to. But it’s concentrated in one research tradition and hasn’t been replicated in the West, so treat the anti-aging claims as promising rather than settled.

The sleep and melatonin regulation side is a another benefit. That effect is direct, people notice it, and it’s what the FDA panel actually evaluated it for. Nobody has to take a lifespan claim on faith to observe whether they’re sleeping better. Typically Eipitalon is used in short cycles 3-5 times a year, rather than continuously.

My take: I love this one. I sleep exceptionally well for at least a month or after a cycle, and that alone makes it worth doing regardless of what the telomere research eventually shows.

DSIP (Emideltide, Delta Sleep-Inducing Peptide)

This one is for sleep, and the only compound the FDA panel voted down in July.

What it is. A nine-amino-acid peptide named for its apparent role in delta-wave sleep. Human trials date back to 1981, which gives it the deepest human research history of the compounds that came before the FDA panel in July 2026 — though the FDA called those trials small, poorly controlled, and inconsistent.

What it does. Proposed for chronic insomnia, narcotic dependence, and opioid withdrawal. The mechanism involves endorphin release, which is also why the FDA flagged a concern about addictive potential.

DSIP was the only one of the seven that failed, voted down 6-7 .

My take: DSIP makes me very sleepy and hung over the next morning. Not one I’d use on a regular basis.

Shop now  Use code SMART15 for extra 15% off

Questions? Reply here or message me. Im happy to answer questions!